MAPS MDMA Therapy Submitted to FDA Could Unlock Psychedelic Industry in 2024

What was said

"MAPS's MDMA clinical trial for PTSD using MDMA as a treatment for PTSD, which has been in clinical trials for several years now, was just submitted last month to the FDA for approval. There is a belief that MDMA therapy will be approved by the FDA at some point here in 2024."

Flores revealed that MAPS submitted its MDMA-assisted therapy for PTSD to the FDA for approval last month, with industry insiders believing approval is likely in 2024. This would mark the first FDA-approved psychedelic therapy and establish a regulatory pathway for other psychedelic drugs like psilocybin and LSD currently in clinical trials.